Recent data suggest that deregulation of the restriction point in the cell-cycle G1 phase appears to be required for the development of neoplasias.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas
Scientific Reports Open Access 09 June 2017
-
The impact of cyclin D1 overexpression on the prognosis of bladder cancer: a meta-analysis
World Journal of Surgical Oncology Open Access 06 March 2014
-
MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia
Oncogene Open Access 06 June 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pardee, A.B. G1 events and regulation of cell proliferation. Science 246, 603–608 (1989).
Pardee, A.B. A restriction point for control of normal animal cell proliferation. Proc. natn. Acad. Sci. U.S.A. 71, 1286–1290 (1974).
Weinberg, R.A. The retinoblastoma protein and cell cycle control. Cell 81, 323–330 (1995).
Sherr, C.J. & Roberts, J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9, 1149–1163 (1995).
Baldin, V., Lukas, J., Marcote, M.J., Pagano, M. & Draetta, G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7, 812–821 (1993).
Lukas, J., Bartkova, J., Rohde, M., Strauss, M. & Bartek, J. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Molec. Cell. Biol. 15, 2600–2611 (1995).
Lukas, J. et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 375, 503–506 (1995).
Koh, J., Enders, G.H., Dynlacht, B. & Harlow, E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375, 506–510 (1995).
Matsushime, H. et al. Identification and properties of an atypical catalytic subunit (p34PSKJ3/cdk4) for mammalian D type G1 cyclins. Cell 71, 323–334 (1992)
Bates, S. & Peters, G. Cyclin D1 as a cellular protooncogene. Sem. Cancer Biol. 6, 73–82 (1995).
Schmidt, E.E., Ichimura, K., Reifenberger, G. & Collins, V.P. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of gliobiastoma. Cancer Res. 54, 6321–6324 (1994).
Wölfel, T. et al. A pl6INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281–1284 (1995).
Merlo, A. et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTSl in human cancers. Nature Med. 1, 686–692 (1995).
Lukas, J., Aagaard, L., Strauss, M. & Bartek, J. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res. 55, 4818–4823 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Strauss, M., Lukas, J. & Bartek, J. Unrestricted cell cycling and cancer. Nat Med 1, 1245–1246 (1995). https://doi.org/10.1038/nm1295-1245
Issue Date:
DOI: https://doi.org/10.1038/nm1295-1245
This article is cited by
-
Novel B, C-ring truncated deguelin derivatives reveals as potential inhibitors of cyclin D1 and cyclin E using molecular docking and molecular dynamic simulation
Molecular Diversity (2022)
-
Prognostic Significance of Cyclin D1 Expression in Renal Cell Carcinoma: a Systematic Review and Meta-analysis
Pathology & Oncology Research (2020)
-
Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas
Scientific Reports (2017)
-
Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss
Cellular Oncology (2017)
-
The impact of cyclin D1 overexpression on the prognosis of bladder cancer: a meta-analysis
World Journal of Surgical Oncology (2014)